Why Krystal Biotech's Shares Rose More Than 77% This Week

·3-min read
Why Krystal Biotech's Shares Rose More Than 77% This Week

Krystal Biotech (NASDAQ: KRYS) saw its shares climb more than 77% this week, according to data provided by S&P Global Market Intelligence. The clinical-stage gene therapy company's stock got its bounce when Krystal announced on Monday that its lead program, Vyjuvek, had gone through its successful phase 3 trial to treat dystrophic epidermolysis bullosa (DEB), a rare inherited disease. DEB patients deal with frequent skin infections from open wounds and are at an increased risk of developing squamous cell carcinoma.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting